LOGIN
Loading...
Search Filters
Date Range
toReport Types
Condition
Region of the Body
See all (5)
Specialties
See all (18)
Emerging Treatments
OE Recommends Topics
Multimedia
Journal
Conference Series
Evidence Series
Showing 1 - 12 of 12
Local peroperative treatment of bisphosphonate improves knee prosthesis fixation
Acta Orthop. 2007 Dec;78(6):795-9
Comparison of risedronate, alendronate, zoledronate, and ibandronate in those with low BMD
Bone. 2016 Aug;89:52-8
Adherence to weekly oral BP therapy versus quarterly IV BP therapy at varying health literacy level
J Bone Miner Metab. 2018 Sep;36(5):589-595. doi: 10.1007/s00774-017-0867-y
Denosumab increases BMD and reduces bone turnover vs monthly oral bisphosphonate
Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.
Network meta-analysis of current drug options for the treatment of osteoporosis in men
PLoS One. 2015 May 26;10(5):e0128032
Zoledronic Acid, alendronate, and risedronate reduce vertebral, nonvertebral, and hip fracture
Osteoporos Int. 2016 Nov;27(11):3289-3300
Bisphosphonates effective in osteoporotic males in terms of fracture, BMD, and biomarkers
Osteoporos Int. 2015 Sep;26(9):2355-63.
Zoledronic acid: best overall bisphosphonate treatment for osteoporosis fractures
Semin Arthritis Rheum. 2011 Feb;40(4):275-84.e1-2.
Revision THR: Bisphosphonate rinse of morcellised bone grafts prevents bone resorption
J Bone Joint Surg Br. 2006 Aug;88(8):993-6
Network meta-analysis of anti-osteoporosis therapies for oral glucocorticoid users
Osteoporos Int. 2016 Jun;27(6):1989-98
Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates
J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70
.jpg)
Zoledronic acid has no continued benefit beyond 6 years for osteoporosis
J Bone Miner Res. 2015 May;30(5):934-44.
Showing 1 - 12 of 12